RANKL exacerbates atopic dermatitis by amplifying keratinocyte barrier dysfunction and allergic skin inflammation
International Immunopharmacology · 2026-12 · 191 · 117668
DOI: 10.1016/j.intimp.2026.117668 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026-12. Verfasst von So-Young Rah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Jeonbuk National University Medical School, Jeonju 54907, Republic of Korea. Die Arbeit nennt 18 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a chronic inflammatory skin disease driven by epidermal barrier dysfunction and immune dysregulation. Although receptor activator of nuclear factor-kappa B ligand (RANKL) is known to modulate mucosal allergies, its specific impact on skin barrier differentiation and inflammatory pathways remains unclear. This study aimed to identify RANKL as a pathological amplifier of epidermal barrier dysfunction and Th2-mediated inflammation in atopic dermatitis (AD), and to elucidate its downstream intracellular signaling mechanisms. Serum RANKL levels were quantified in AD patients. The functional impact of RANKL was evaluated in a 2,4-dinitrofluorobenzene (DNFB)-induced mouse model using siRNA-mediated silencing and recombinant RANKL (rRANKL) administration. In HaCaT cells, the direct effects of RANKL on barrier markers and inflammatory mediators were assessed. Serum RANKL levels were significantly elevated in AD patients and positively correlated with thymic stromal lymphopoietin (TSLP) and IgE. In mice, RANKL inhibition attenuated skin lesions, suppressed Th2 cytokines, pro-inflammatory mediator, and alarmins, and reduced caspase-1 activity. Conversely, rRANKL exacerbated AD symptoms and increased caspase-1 activity. In vitro, RANKL stimulation directly impaired the expression of skin barrier proteins while upregulating pro-inflammatory cytokines. Mechanistically, rRANKL activated p38 and extracellular signal-regulated kinase (ERK) phosphorylation, whereas pretreatment with p38 or ERK inhibitors suppressed the induction of inflammatory cytokines. Conclusion, RANKL serves as a context-dependent amplifier in established AD that exacerbates skin barrier impairment and allergic inflammation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Jeonbuk National University Medical School, Jeonju 54907, Republic of Korea.
- BioChip Research Center, Hoseo University, Asan 31499, Republic of Korea.
- Department of Bio-Convergence System, Graduate School, Hoseo University, Asan 31449, Republic of Korea.
- Department of Food and Biotechnology, Graduate School, Hoseo University, Asan 31499, Republic of Korea.
- BioChip Research Center, Hoseo University, Asan 31499, Republic of Korea; Department of Bio-Convergence System, Graduate School, Hoseo University, Asan 31449, Republic of Korea; Department of Food and Biotechnology, Gra…
Förderung
- National Research Foundation of Korea
Zitieren
APA
Rah, S. Y., Kim, H. Y., Jeong, K. M., Choi, Y. J., Yang, S. B., Kwon, M., & Jeong, H. J. (2026). RANKL exacerbates atopic dermatitis by amplifying keratinocyte barrier dysfunction and allergic skin inflammation. International Immunopharmacology, 191, 117668. https://doi.org/10.1016/j.intimp.2026.117668
Vancouver
Rah SY, Kim HY, Jeong KM, Choi YJ, Yang SB, Kwon M, et al. RANKL exacerbates atopic dermatitis by amplifying keratinocyte barrier dysfunction and allergic skin inflammation. International Immunopharmacology. 2026;191:117668. doi:10.1016/j.intimp.2026.117668
BibTeX
@article{Rah2026,
author = {Rah, So-Young and Kim, Hee-Yun and Jeong, Kyung-Min and Choi, Yu-Jin and Yang, Seong-Been and Kwon, Minsung and Jeong, Hyun-Ja},
title = {RANKL exacerbates atopic dermatitis by amplifying keratinocyte barrier dysfunction and allergic skin inflammation},
journal = {International Immunopharmacology},
year = {2026},
volume = {191},
pages = {117668},
doi = {10.1016/j.intimp.2026.117668}
}
EUVIMED